Abstract B117: Phase 1 study of CM24 in combination with nivolumab in patients with advanced pancreatic cancer - Survival, potential biomarker and effect on neutrophil extracellular traps (NETs)
Borazanci E, Pant S, Perets R, Golan T, Al Hallak M, Cecchini M, Maierson T, David H, Schickler M, Reuveni H. Abstract B117: Phase 1 study of CM24 in combination with nivolumab in patients with advanced pancreatic cancer - Survival, potential biomarker and effect on neutrophil extracellular traps (NETs). Cancer Research 2024, 84: b117-b117. DOI: 10.1158/1538-7445.panca2023-b117.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinoma patientsTumor-infiltrating lymphocytesPancreatic ductal adenocarcinomaNeutrophil extracellular trapsCarcinoembryonic antigen cell adhesion molecule 1Dose-escalation partPancreatic cancer survivalImmune evasionExtracellular trapsEscalation partPatient biopsiesPotential biomarkersRandomized phase 2 studyCompared to healthy volunteersControl immune evasionDisease control ratePhase 1/2 studyAnti-tumor immunitySecond-line therapyCancer survivalPhase 2 studyPhase 1 studyCell adhesion molecule 1Adhesion molecule 1Patient survival data